Stockreport

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors [Yahoo! Finance]

Werewolf Therapeutics, Inc.  (HOWL) 
PDF - Encouraging single agent clinical activity with three objective responses, including a durable confirmed complete response - - Monotherapy recommended dose for expa [Read more]